Log in

Relevant bibliographies by topics / Tumstatin / Journal articles

Journal articles on the topic 'Tumstatin'

To see the other types of publications on this topic, follow the link: Tumstatin.

Author: Grafiati

Published: 4 June 2021

Last updated: 21 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Tumstatin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Wang, Shu Jing, Jia Liu, Fei Wang, Ning Chen, Shan Jiang, Lin Liu, Ying Zhao, and Xiao Dan Zhang. "Tumstatin 7 Peptide Affect Biological Activity of B16 Melanoma Cell." Advanced Materials Research 641-642 (January 2013): 915–18. http://dx.doi.org/10.4028/www.scientific.net/amr.641-642.915.

Full text

Abstract:

To study the effect of biological activity of Tumstatin 7 peptide on the cell proliferation and apoptosis of B16 melanoma. Tumstatin 7 peptide was synthesized and its purity is 98.4532% by high-performance liquid chromatography. The effect of 7 peptide on B16 melanoma was observed by MTT, cell growth curve, the observation of the transmission electron microscope (TEM). 7 peptide can significantly inhibit B16 melanoma cell proliferation, showing dose- and time-dependent .Its IC50 was 72.53 μg/ml.The morphology of B16 melanoma cell was obviously changed by TEM, such as karyopyknosis and apoptotic bodies. So7 peptides can inhibit the proliferation of melanoma cells and promote melanoma cells apoptosis. It will be of great potential value to melanoma treatment.

APA, Harvard, Vancouver, ISO, and other styles

2

Bonn, Dorothy. "Tumstatin hints at how angiogenesis inhibitors work." Lancet Oncology 3, no. 2 (February 2002): 71. http://dx.doi.org/10.1016/s1470-2045(02)00641-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

WANG, WEI, CHUN-XIAO XU, GUO-SHENG HOU, YOU-GEN CHEN, JIA-XUAN XIN, and XIAN-XI LIU. "Downregulation of tumstatin expression by overexpression of ornithine decarboxylase." Oncology Reports 30, no. 5 (August 29, 2013): 2042–48. http://dx.doi.org/10.3892/or.2013.2708.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Maeshima, Y. "Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis." Science 295, no. 5552 (January 4, 2002): 140–43. http://dx.doi.org/10.1126/science.1065298.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Oruc, Y., and S. Aydin. "Blood and aqueous humor tumstatin concentrations associated with diabetic retinopathy." Annals of Systems Biology 3, no. 1 (April 25, 2020): 025–28. http://dx.doi.org/10.17352/asb.000008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Nissen, Gyde, Henrike Hollaender, Francesca S. M. Tang, Michael Wegmann, Lars Lunding, Christina Vock, Anna Bachmann, et al. "Tumstatin fragment selectively inhibits neutrophil infiltration in experimental asthma exacerbation." Clinical & Experimental Allergy 48, no. 11 (August 28, 2018): 1483–93. http://dx.doi.org/10.1111/cea.13236.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gu, Quliang, Tianyuan Zhang, Jinxian Luo, and Fangyu Wang. "Expression, purification, and bioactivity of human tumstatin from Escherichia coli." Protein Expression and Purification 47, no. 2 (June 2006): 461–66. http://dx.doi.org/10.1016/j.pep.2006.01.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Caudroy, Stephanie, Joel Cucherousset, Marianne Lorenzato, Jean-Marie Zahm, Corinne Martinella-Catusse, Myriam Polette, and Philippe Birembaut. "Implication of tumstatin in tumor progression of human bronchopulmonary carcinomas." Human Pathology 35, no. 10 (October 2004): 1218–22. http://dx.doi.org/10.1016/j.humpath.2004.06.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Xu, Chun-xiao, Xian-xi Liu, Guo-sheng Hou, Yun-fei Yan, Shi-min Chen, Wei Wang, Guang-shui Jiang, Bin Liu, and Jia-xuan Xin. "The expression of tumstatin is down-regulated in renal carcinoma." Molecular Biology Reports 37, no. 5 (August 18, 2009): 2273–77. http://dx.doi.org/10.1007/s11033-009-9718-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Wei, C., A. Y. Xun, X. X. Wei, J. Yao, J. Y. Wang, R. Y. Shi, G. H. Yang, et al. "BifidobacteriaExpressing Tumstatin Protein for Antitumor Therapy in Tumor-Bearing Mice." Technology in Cancer Research & Treatment 15, no. 3 (May 11, 2015): 498–508. http://dx.doi.org/10.1177/1533034615581977.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Wang, Shu Jing, Ning Chen, Zhang Yi, Jia Liu, and Bei Bei Xu. "Study on the Biological Activity of Anti-Tumor Peptide of Tumstatin." Advanced Materials Research 183-185 (January 2011): 1509–12. http://dx.doi.org/10.4028/www.scientific.net/amr.183-185.1509.

Full text

Abstract:

Tumstatin anti-tumor peptide of 19peptide can inhibit the proliferation of melanoma cell. To study its effect on the proliferation and apoptosis of different tumor cells and verify its anti-tumor non-specificity, the base sequence of 19peptide was designed and constructed engineering bacteria. The soluble 19peptide was obtained from one step chitin affinity chromatograph. By such experiment as MTT assay, cell growth curve, TUNEL assay，flow cytometry，transmission electron microscopy(TEM), the biological activity of 19peptide was studied. Experiments in vitro identified that obtained 19peptide could inhibit proliferation of hela cell and hepatocarcinoma cell. It also could promote two tumor cells apoptosis. Its anti-tumor effect will lay foundation on its mechanism of action research and clinically tumor therapy in future.

APA, Harvard, Vancouver, ISO, and other styles

12

Thevenard, Jessica, Nicolas Floquet, Laurent Ramont, Elise Prost, Jean-Marc Nuzillard, Manuel Dauchez, Hocine Yezid, et al. "Structural and Antitumor Properties of the YSNSG Cyclopeptide Derived from Tumstatin." Chemistry & Biology 13, no. 12 (December 2006): 1307–15. http://dx.doi.org/10.1016/j.chembiol.2006.10.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Wang, Shujing, Yan Liu, Xuesong Lin, Xue Fu, Jianyong Xu, and Xinghan Liu. "Cloning and biological activity of an anti-tumor peptide of Tumstatin." Frontiers of Biology in China 2, no. 3 (July 2007): 276–83. http://dx.doi.org/10.1007/s11515-007-0040-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Luo, Yi-Qin, Liang-Hua Wang, Qui Yi, and Bing-Hua Jiao. "Expression of soluble, biologically active recombinant human tumstatin in Escherichia coli." Clinical and Experimental Medicine 8, no. 1 (March 2008): 37–42. http://dx.doi.org/10.1007/s10238-008-0154-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Burgess, Janette K., Sarah Boustany, Lyn M. Moir, Markus Weckmann, Justine Y. Lau, Karryn Grafton, Melissa Baraket, et al. "Reduction of Tumstatin in Asthmatic Airways Contributes to Angiogenesis, Inflammation, and Hyperresponsiveness." American Journal of Respiratory and Critical Care Medicine 181, no. 2 (January 15, 2010): 106–15. http://dx.doi.org/10.1164/rccm.200904-0631oc.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Zhang, Pengguo, Qingwei Zhou, Lin Tian, Xiangyu Zhou, Yue Zhou, and Jiajun Chen. "Experimental study of a novel tumstatin on C6 brain glioma in vitro." Oncology Letters 14, no. 3 (June 30, 2017): 2845–51. http://dx.doi.org/10.3892/ol.2017.6507.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Maeshima, Yohei, Mark Manfredi, Corinne Reimer, Kathryn A. Holthaus, Helmut Hopfer, Babi R. Chandamuri, Surender Kharbanda, and Raghu Kalluri. "Identification of the Anti-angiogenic Site within Vascular Basement Membrane-derived Tumstatin." Journal of Biological Chemistry 276, no. 18 (February 7, 2001): 15240–48. http://dx.doi.org/10.1074/jbc.m007764200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Luo, Yi-Qin, Zhou Ming, Liang Zhao, Li-Juan Yao, Hang Dong, Jian-Ping Du, Shuang-Zheng Wu, and Wen Hu. "Decreased tumstatin-mRNA is associated with poor outcome in patients with NSCLC." IUBMB Life 64, no. 5 (March 31, 2012): 423–31. http://dx.doi.org/10.1002/iub.1016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Li, Juan, Jing Luo, Yi-Qin Luo, Ming Zhou, Liang Zhao, Li-Juan Yao, Hang Dong, and Rui-Ning Yang. "Overexpression of tumstatin in genetically modified megakaryocytes changes the proangiogenic effect of platelets." Transfusion 54, no. 8 (March 24, 2014): 2106–17. http://dx.doi.org/10.1111/trf.12617.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Li, Ying-jie, Li-chun Sun, Yan He, Xing-han Liu, Miao Liu, Qi-min Wang, and Xiao-ming Jin. "The anti-tumor properties of two tumstatin peptide fragments in human gastric carcinoma." Acta Pharmacologica Sinica 30, no. 9 (August 24, 2009): 1307–15. http://dx.doi.org/10.1038/aps.2009.111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Yasuda, Jumpei, Muneyoshi Okada, and Hideyuki Yamawaki. "T3 peptide, a fragment of tumstatin, prevents the ischemia-reperfusion injury in cardiomyocytes." Proceedings for Annual Meeting of The Japanese Pharmacological Society WCP2018 (2018): PO1–2–65. http://dx.doi.org/10.1254/jpssuppl.wcp2018.0_po1-2-65.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Sun, Chao, Dongyang He, Chao Ma, Zhenyue Gao, Yijun Chen, and Shuzhen Wang. "Bifunctional Fusion Proteins Derived from Tumstatin and 4-1BBL for Targeted Cancer Therapy." Molecular Pharmaceutics 16, no. 2 (December 19, 2018): 867–76. http://dx.doi.org/10.1021/acs.molpharmaceut.8b01190.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Harkness, Louise Margaret, Markus Weckmann, Matthias Kopp, Tim Becker, Anthony Wayne Ashton, and Janette Kay Burgess. "Tumstatin regulates the angiogenic and inflammatory potential of airway smooth muscle extracellular matrix." Journal of Cellular and Molecular Medicine 21, no. 12 (June 13, 2017): 3288–97. http://dx.doi.org/10.1111/jcmm.13232.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Maeshima, Yohei, Pablo C. Colorado, and Raghu Kalluri. "Two RGD-independent αvβ3Integrin Binding Sites on Tumstatin Regulate Distinct Anti-tumor Properties." Journal of Biological Chemistry 275, no. 31 (June 2, 2000): 23745–50. http://dx.doi.org/10.1074/jbc.c000186200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Gu, Quliang, Cihuang Sun, Jinxian Luo, Tianyuan Zhang, and Lijing Wang. "Inhibition of angiogenesis by a synthetic fusion protein VTF derived from vasostatin and tumstatin." Anti-Cancer Drugs 25, no. 9 (October 2014): 1044–51. http://dx.doi.org/10.1097/cad.0000000000000134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Zan, Jinhang, Xin He, Wei Long, and Peixun Liu. "Insights into binding modes of tumstatin peptide T7 with the active site of αvβ3integrin." Molecular Simulation 38, no. 6 (May 2012): 498–508. http://dx.doi.org/10.1080/08927022.2011.649428.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Naling, Song, He Xin, Zhao Qiren, Yan Tingdong, and Wen Lei. "Cloning and expression of the tumstatin active peptides-T7 and its derivant-T7-NGR." Clinical and Experimental Medicine 9, no. 2 (February 3, 2009): 165–71. http://dx.doi.org/10.1007/s10238-008-0029-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Wang, Shu Jing, Shan Jiang, Jia Liu, Fei Wang, Ning Chen, Lin Liu, Ying Zhao, and Xiao Dan Zhang. "The Effect of T-7 Peptide on Human Non-Small-Cell Carcinoma A549 Cells." Advanced Materials Research 641-642 (January 2013): 820–23. http://dx.doi.org/10.4028/www.scientific.net/amr.641-642.820.

Full text

Abstract:

7 peptide of Tumstatin(T-7 peptide) is composed of 185-191 amino acids. To study T-7 peptide antitumor activity to human non-small-cell carcinoma(A549), T-7 peptide was designed and synthesized by amino acid synthesizer. Its purity ran up to 98.45% by HPLC and MS. The effect of T-7 peptide on A549 cell growth was observed by MTT assay, growth curve and transmission electron microscopy(TEM). T-7 peptide had the effects of suppressing A549 cell growth and promoting its apoptosis, showing dose- and time-dependent. Its IC50 was 92.84 μg/ml. TEM also revealed that A549 cell treated with T-7 peptide appeared apoptotic morphology,such as cell pyknosis and mitochondrial vacuoles formed. While T-7 peptide had little effect on human umbilical vein endothelial cells(ECV304). These researches were significant to treat human non-small-cell carcinoma in the future.

APA, Harvard, Vancouver, ISO, and other styles

29

Wang, Shu Jing, Fei Wang, Jia Liu, Shan Jiang, Ning Chen, Lin Liu, Ying Zhao, and Xiao Dan Zhang. "Effect of Tumstatin T-7 Peptide on HepG-2 Cells and Human Umbilical Vein Endothelial Cells." Advanced Materials Research 641-642 (January 2013): 744–47. http://dx.doi.org/10.4028/www.scientific.net/amr.641-642.744.

Full text

Abstract:

The direct anti-tumor T-7 peptide of tumstatin was obtained to study its effect on human hepatoma cells (HepG-2) and human umbilical vein endothelial cells (ECV304). T-7 peptide was synthesized and its purity was up to 98.5%. MTT assay, growth curve, transmission electron microscopy(TEM) were used to detect the proliferation inhibition and pro-apoptotic function. MTT experiments and growth curve experiments showed that the survival of human hepatoma cells (HepG-2) decreased in a time- and dose-dependent way with the concentration of T-7 peptide increased. T-7 peptide can induce apoptosis of HepG-2 significantly. Apoptosis features were observed by TEM. However, the inhibition of T-7 peptide on human umbilical vein endothelial cells (ECV304) was weaker. Experiments showed thatT-7 peptide can affect HepG-2 cells. It had a certain therapeutic effect on human hepatocellular carcinoma. T-7 peptide have little effect on ECV304 cells, which means it didn’t influence the formation of tumor angiogenesis and normal cells

APA, Harvard, Vancouver, ISO, and other styles

30

S Boosani, Chandra, Ashok K Verma, and Akulapalli Sudhakar. "Validation of Different Systems for Tumstatin Expression and its in-vitro and iv-vivo Activities." Journal of Cancer Science & Therapy 01, no. 01 (2009): 008–18. http://dx.doi.org/10.4172/1948-5956.1000002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Yao, Bin, Qiu-Ming He, Ling Tian, Fei Xiao, Yu Jiang, Ru Zhang, Gang Li, et al. "Enhanced Antitumor Effect of the Combination of Tumstatin Gene Therapy and Gemcitabine in Murine Models." Human Gene Therapy 16, no. 9 (September 2005): 1075–86. http://dx.doi.org/10.1089/hum.2005.16.1075.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Sun, Chao, Dongyang He, Chao Ma, Zhenyue Gao, Yijun Chen, and Shuzhen Wang. "Correction to “Bifunctional Fusion Proteins Derived from Tumstatin and 4–1BBL for Targeted Cancer Therapy”." Molecular Pharmaceutics 16, no. 12 (November 14, 2019): 5085. http://dx.doi.org/10.1021/acs.molpharmaceut.9b01144.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Chang, Kyung Hwa, Jong Min Lee, Hee Kyoung Jeon, and In Sik Chung. "Improved production of recombinant tumstatin in stably transformed Trichoplusia ni BTI Tn 5B1-4 cells." Protein Expression and Purification 35, no. 1 (May 2004): 69–75. http://dx.doi.org/10.1016/j.pep.2004.01.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Esipov, Roman, Ksenia Beyrakhova, Vera Likhvantseva, Evgenia Stepanova, Vasily Stepanenko, Maria Kostromina, Yulia Abramchik, and Anatoly Miroshnikov. "Antiangiogenic and antivascular effects of a recombinant tumstatin-derived peptide in a corneal neovascularization model." Biochimie 94, no. 6 (June 2012): 1368–75. http://dx.doi.org/10.1016/j.biochi.2012.03.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

REN, Na, Liang-hua WANG, Yun GAO, Ming-juan SUN, Yu-liang JIAO, Ai-yun GUO, and Bing-hua JIAO. "Expression of Tumstatin_183-230-TRAIL fusion protein and identification of its biological functions." Academic Journal of Second Military Medical University 28, no. 5 (October 13, 2008): 474–78. http://dx.doi.org/10.3724/sp.j.1008.2008.00474.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

WANG, YANG, RUO-FENG YIN, and JIA-SONG TENG. "Tumstatin induces apoptosis and stimulates phosphorylation of p65NF-κB in human osteoblastic osteosarcoma Saos-2 cells." Oncology Reports 35, no. 6 (April 20, 2016): 3403–8. http://dx.doi.org/10.3892/or.2016.4762.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Yamamoto, Y., Y. Maeshima, H. Kitayama, S. Kitamura, Y. Takazawa, H. Sugiyama, Y. Yamasaki, and H. Makino. "Tumstatin Peptide, an Inhibitor of Angiogenesis, Prevents Glomerular Hypertrophy in the Early Stage of Diabetic Nephropathy." Diabetes 53, no. 7 (June 25, 2004): 1831–40. http://dx.doi.org/10.2337/diabetes.53.7.1831.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Folkman, J. "Tumor Suppression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin." Science's STKE 2006, no. 354 (September 19, 2006): pe35. http://dx.doi.org/10.1126/stke.3542006pe35.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Thevenard, Jessica, Laurent Ramont, Lluis M. Mir, Aurélie Dupont-Deshorgue, François-Xavier Maquart, Jean-Claude Monboisse, and Sylvie Brassart-Pasco. "A new anti-tumor strategy based on in vivo tumstatin overexpression after plasmid electrotransfer in muscle." Biochemical and Biophysical Research Communications 432, no. 4 (March 2013): 549–52. http://dx.doi.org/10.1016/j.bbrc.2013.02.074.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

HWANG-BO, JEON, JONG-HWA PARK, and IN SIK CHUNG. "Tumstatin induces apoptosis mediated by Fas signaling pathway in oral squamous cell carcinoma SCC-VII cells." Oncology Letters 10, no. 2 (May 25, 2015): 1016–22. http://dx.doi.org/10.3892/ol.2015.3261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

ZHANG, Guang-mei, Ying-mei ZHANG, Song-bin FU, Xing-han LIU, Xue FU, Yan YU, and Zhi-yi ZHANG. "Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells." Chinese Medical Journal 121, no. 22 (November 2008): 2324–30. http://dx.doi.org/10.1097/00029330-200811020-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Tanabe, Katsuyuki, Yohei Maeshima, Yasufumi Sato, and Jun Wada. "Antiangiogenic Therapy for Diabetic Nephropathy." BioMed Research International 2017 (2017): 1–12. http://dx.doi.org/10.1155/2017/5724069.

Full text

Abstract:

Angiogenesis has been shown to be a potential therapeutic target for early stages of diabetic nephropathy in a number of animal experiments. Vascular endothelial growth factor (VEGF) is the main mediator for abnormal angiogenesis in diabetic glomeruli. Although beneficial effects of anti-VEGF antibodies have previously been demonstrated in diabetic animal experiments, recent basic and clinical evidence has revealed that the blockade of VEGF signaling resulted in proteinuria and renal thrombotic microangiopathy, suggesting the importance of maintaining normal levels of VEGF in the kidneys. Therefore, antiangiogenic therapy for diabetic nephropathy should eliminate excessive glomerular angiogenic response without accelerating endothelial injury. Some endogenous antiangiogenic factors such as endostatin and tumstatin inhibit overactivation of endothelial cells but do not specifically block VEGF signaling. In addition, the novel endothelium-derived antiangiogenic factor vasohibin-1 enhances stress tolerance and survival of the endothelial cells, while inhibiting excess angiogenesis. These factors have been demonstrated to suppress albuminuria and glomerular alterations in a diabetic mouse model. Thus, antiangiogenic therapy with promising candidates will possibly improve renal prognosis in patients with early stages of diabetic nephropathy.

APA, Harvard, Vancouver, ISO, and other styles

43

Sudhakar, Akulapalli, and Chandra S. Boosani. "Retraction Note: Inhibition of Tumor Angiogenesis by Tumstatin: Insights into Signaling Mechanisms and Implications in Cancer Regression." Pharmaceutical Research 38, no. 2 (January 15, 2021): 377. http://dx.doi.org/10.1007/s11095-020-02974-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

He, Yan, Yang Jiang, Ying-Jie Li, Xing-Han Liu, Lei Zhang, Li-Juan Liu, Hang Shi, Hui-Ning Li, Yong-Cu Ma, and Xiao-Ming Jin. "19-peptide, a fragment of tumstatin, inhibits the growth of poorly differentiated gastric carcinoma cellsin vitroandin vivo." Journal of Gastroenterology and Hepatology 25, no. 5 (April 28, 2010): 935–41. http://dx.doi.org/10.1111/j.1440-1746.2009.06209.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Sudhakar, A., H. Sugimoto, C. Yang, J. Lively, M. Zeisberg, and R. Kalluri. "Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by v 3 and 5 1 integrins." Proceedings of the National Academy of Sciences 100, no. 8 (April 7, 2003): 4766–71. http://dx.doi.org/10.1073/pnas.0730882100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Yasuda, Jumpei, Muneyoshi Okada, and Hideyuki Yamawaki. "Protective effect of T3 peptide, an active fragment of tumstatin, against ischemia/reperfusion injury in rat heart." Journal of Pharmacological Sciences 139, no. 3 (March 2019): 193–200. http://dx.doi.org/10.1016/j.jphs.2019.01.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Yasuda, Jumpei, Muneyoshi Okada, and Hideyuki Yamawaki. "T3 peptide, an active fragment of tumstatin, inhibits H 2 O 2 -induced apoptosis in H9c2 cardiomyoblasts." European Journal of Pharmacology 807 (July 2017): 64–70. http://dx.doi.org/10.1016/j.ejphar.2017.04.032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Pasco, Sylvie, Laurent Ramont, Lydie Venteo, Michel Pluot, François-Xavier Maquart, and Jean-Claude Monboisse. "In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model." Experimental Cell Research 301, no. 2 (December 2004): 251–65. http://dx.doi.org/10.1016/j.yexcr.2004.07.036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Eikesdal, H. P., H. Sugimoto, G. Birrane, Y. Maeshima, V. G. Cooke, M. Kieran, and R. Kalluri. "Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity." Proceedings of the National Academy of Sciences 105, no. 39 (September 25, 2008): 15040–45. http://dx.doi.org/10.1073/pnas.0807055105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Yu, Wei, Jun'an Hu, Haiwei Le, Yigao Lu, Weihua Xu, Wangfang Yu, and Wei Shen. "Tumstatin attenuates the promotion effect of IL-17 secreted by Th17 cells on the stemness maintenance of glioma cells." Pathology - Research and Practice 223 (July 2021): 153463. http://dx.doi.org/10.1016/j.prp.2021.153463.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!